Research and Development

Showing 15 posts of 9599 posts found.

janssen_latest_logo_on_sign

Janssen’s Darzalex combo shows strong overall survival benefit at ASH 2019

December 10, 2019 Manufacturing and Production, Research and Development ASH 19, Janssen, darzalex, pharma

Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone …
abbvie_0

Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia

December 9, 2019 Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax

AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …
shutterstock_138095450

Transactions in the pharma sector: Through the EU merger review looking-glass

December 9, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, feature, mergers & acquisitions, pharma

With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …
jj

J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma

December 9, 2019 Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …
sage_logo

Sage Therapeutics’ depression drug falls short at Phase 3

December 6, 2019 Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure

Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …
top_10_image_43_0

Top Ten most popular articles on Pharmafile.com this week

December 6, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, NHS, corruption, lung cancer, opiods crisis, opioids

Corruption and bribery feature heavily in the news this week. A recently exposed 1997 email chain shows Dr Richard Sackler, …

Partnership with payers: Communicating and negotiating with impact

December 6, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NDA, market access, pharma

NDA’s Lisa Peluso, Director, Coaching and Client Engagement, outlines key strategies for interacting with audiences and payers while maximising team …
dr-torbett-696x464

Dr Richard Torbett is named as the new Chief Executive of the ABPI

December 5, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its new Chief Executive. He will …

FDA-approved drug can repair gut leakiness in types of bowel disease

December 5, 2019 Research and Development biomedicine, bowel, bowel cancer, bowel disease

A team of biomedical scientists at the University of California has found that a FDA-approved drug for treating rheumatoid arthritis …
allergan

Allergan’s ubrogepant doses smash primary endpoints in acute treatment of migraine

December 5, 2019 Research and Development Allergan, FDA, pharma, ubrogepant

New Phase 3 data has been released showing that both 50mg and 100mg doses of Allergan’s ubrogepant met their primary …
image3

Patient experience: Living with desmoid fibromatosis

December 4, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing desmoid fibrosis, feature, patient experience, pharma, rare disease

Lisa Pascoe lives with a rare, benign desmoid tumour in her abdomen. She opens up to Pharmafocus on her diagnosis …
fdaoutsideweb_18

Trump’s new FDA nominee advances in the Senate

December 4, 2019 Research and Development Big Pharma, FDA, FDA commissioner, Trump, US Pharma

Dr Stephen Hahn, President Donald Trump’s FDA nominee, has advanced his nomination to the full Senate chamber. The vote was …
contraceptive-pills-849413_960_720

Male birth control drug may hold promise for treating lung cancer, Chinese study finds

December 4, 2019 Research and Development Cancer Immunotherapy, Chinese Pharmaceuticals, Male Birth Control, lung cancer

A drug for male birth control may hold promise for treating lung cancer patients when treatments like immunotherapy do not …

FDA approves Johnson & Johnson cataract treatment

December 4, 2019 Research and Development

Johnson & Johnson has secured approval from the FDA for its Tecnis Toris II 1-Piece Intraocular Lens (IOL).                                                                               &nbs
tecentriq

Roche’s Tecentriq combo scores FDA approval in non-small cell lung cancer

December 4, 2019 Research and Development, Sales and Marketing FDA, NSCLC, Roche, pharma, tecentriq

Roche’s immunotherapy Tecentriq (atelizumab) has chalked up another approval from the FDA, this time in combination with the chemotherapy Abraxane …
The Gateway to Local Adoption Series

Latest content